Introduction
Malignant gliomas (MGs) account for approximately 70 % of the 22,500 new cases of malignant primary brain tumors in the United States each year. Despite treatment, the median survival is only 15 months for patients with glioblastomas (GBM) and 2-5 years for patients with anaplastic astrocytomas (AA) [1] . Chemotherapy has shown only 1 3 modest eicacy against MGs. Better agents are needed to improve the outcome of patients with MG.
Notch, a cell surface protein receptor involved in transmitting growth and proliferation signals is often deregulated in cancer [2, 3] . Two membrane bound Notch families, Jagged and Delta, have been described with multiple ligands identiied to date. After ligand binding, two successive proteolytic cleavage steps occur. The resulting active form notch intracellular domain (NICD) translocates to the nucleus, where it binds a transcriptional repressor, thus activating target genes [4] . Blocking Notch signaling via γ-secretase inhibition produces a slower growing, less transformed cancer cells [4, 5] .
Several studies highlight the association between Notch signaling and tumorigenesis. Inappropriate activation of Notch signaling has been shown to result in proliferation, dediferentiation, and prevention of apoptosis in a variety of cancers [6] [7] [8] [9] [10] . Inhibition of Notch1 in embryonal brain tumor depletes the cancer stem cell population and induces diferentiation [5] . In iniltrating gliomas, Notch1 signaling was found to enhance nestin expression, suggesting that it exerts a direct efect on maintenance of the undiferentiated phenotype, and thus may contribute to glioma growth [11, 12] .
RO4929097, a γ-secretase inhibitor (GSI), is an orally administered antagonist of Notch signaling by preventing a necessary intramembranous cleavage that liberates NICD, a transcriptional co-activator. Although bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor, has been utilized in the treatment of iniltrating gliomas, its use has been associated with adoption of an invasive phenotype. Here we studied the combination of GSI and bevacizumab in bevacizumab-naïve MG subjects. Notch promotes tumor cell invasion and is also involved in pathologic angiogenesis [13, 14] . Thus, the rationale is that inhibition of Notch signaling pathway may provide direct anti-tumor activity, mitigate invasive efect, and enhance antiangiogenic efect via promotion of "nonfunctional" tumor angiogenesis.
Materials and methods

Protocol objectives
The primary objective of this study was to assess the safety proile of RO4929097 in combination with bevacizumab and to determine a recommended Phase II dose of RO4929097 in combination with bevacizumab in patients with recurrent MGs. The secondary objectives were to describe the toxicity associated with this combination regimen, to assess the pharmacokinetics of RO4929097 in combination with bevacizumab, to assess the proportion of patients alive and progression free at 6 months (PFS6), to assess the median overall survival (OS) of the trial population, and to explore potential prognostic biomarkers from glioma tissue at baseline and potential association with Notch pathway inhibition.
Patient eligibility
This protocol (ClinicalTrials.gov number NCT01189240) was IRB approved, and all study patients signed a written informed consent. Study patients, 18 years of age or older, must have had histologically proven MG which was progressive following radiation therapy and temozolomide chemotherapy. Patients must have had measurable contrastenhancing recurrent MG by MRI within 2 weeks of starting treatment. They must have recovered from severe toxicity of prior therapy. An interval of at least 28 days must have elapsed since any prior surgery. Study patients must have had a Karnofsky Performance Status ≥60. They must have had adequate bone marrow and organ function. Women of childbearing potential were required to have a negative pregnancy test within 10-14 days.
Exclusion criteria include serious concurrent infection or medical illness, prior treatment with γ-secretase inhibitor or bevacizumab, serologic positivity for Hepatitis A, B or C, or those who had cirrhosis, or pregnant women or those who were breastfeeding. The remaining exclusion criteria were similar to those of previous brain tumor therapeutic clinical trials.
Trial design
In this open-label phase I trial with standard 3 + 3 design, study patients received RO4929097 orally for 3 days on/4 days of each week in 4 week cycles (Days 1-3, 8-10, 15-17, and 22-24) and bevacizumab 10 mg/kg every 2 weeks by intravenous infusion in an outpatient setting on Days 1 and 15. Patients received brain MRIs with contrast every 8 weeks (2 cycles of RO4929097 and 4 doses of IV bevacizumab). Three pre-speciied RO4929097 doses (5, 10, and 20 mg) were evaluated. Three patients per cohort were treated at each RO4929097 dose level and the dose escalation occurred in a stepwise fashion with an expansion to a total of six patients at the putative MTD/or the highest dose (20 mg). A cycle of therapy was 28 days. To accommodate pharmacokinetic sampling, the irst infusion of bevacizumab for study patients was on day 2 or 3 of cycle 1. The second infusion was on day 15 of cycle 1 and had to have been completed prior to administration of irst weekly dose of RO4929097. Treatment cycles were repeated until disease progression or until development of signiicant toxicities.
The recommended phase II dose of the combination therapy was deined as the maximum administered dose of RO4929097 at which 0 or 1 of 6 study patients experience a DLT. If dose escalation reached the highest dose level with ≤1 DLT in 6 patients, then that dose was declared the MTD.
Toxicity assessment
Safety and toxicity assessments were obtained at each study visit. Adverse events and other symptoms were graded according to the NCI Common Terminology Criteria of Adverse Events 4.0 (CTCAE version 4.0). A standard deinition of dose limiting toxicity (DLT) was used. For study patients who experienced a DLT, RO4929097 and/or bevacizumab was held. Patients who experienced a grade 4 non-hematological DLT was taken of treatment. If the trial patient recovered [≤grade 1 (or tolerable grade 2 for non-hematologic toxicity) or ≤baseline] a dose reduction was required for subsequent doses, with a maximum of 2 dose reductions. Hematological toxicities were considered dose limiting if any of the following occurred: ANC of ≤500/µL or second occurrence of ANC < 1000/µL (grade 3), PLTs ≤ 25,000/µL or second occurrence of platelets <50,000/µL (grade 3), febrile neutropenia, or thrombocytopenic bleeding (deined as platelets <50,000/µL and associated with clinically signiicant bleeding).
Response assessment
Although response was not the primary endpoint of this trial, patients with measurable disease were assessed by the RANO (Response Assessment in Neuro-Oncology) criteria every 8 weeks with a contrast-enhanced brain MRI scan and characterized into the following categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).
Tissue biomarker analysis: NICD staining of subject tissues
Indirect immunoluorescence assays of parain embedded MG tissues were performed as previously described on pretreated tumor tissue of 9 of 13 enrolled subjects [15, 16] . After deparainization, slides were incubated with primary antibodies against activated Notch1 (Abcam, ab8925) at 1:200 concentration overnight at 4 °C. This antibody is speciic for the human N-terminal sequence of the cleaved Notch. Slides were subsequently probed with Alexa Fluor 488 secondary antibody (Invitrogen, 1:1000). Cell nuclei were counterstained with DAPI (1 µg/ml). All slides were photographed with Leica SP5 confocal microscope.
Pharmacokinetic studies
The objective of the pharmacokinetic studies was to evaluate the efect of bevacizumab on the plasma pharmacokinetics of RO4929097. Sampling was performed to deine the time course of the concentration of RO4929097 in plasma during the 24 h dosing interval for the doses given on days 1 and 15 of cycle 1 to all patients enrolled in the Phase I part of the clinical trial. The irst dose of bevacizumab was not given until day 2 or 3 after all pharmacokinetic samples for the initial dose of RO4929097 were collected. The RO4929097 dose on day 15 was given shortly after completing bevacizumab infusion. Blood was drawn into tubes containing sodium heparin before and at 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h after taking RO4929097 on days 1 and 15. The sample collection tubes were mixed with the anticoagulant and placed over ice until centrifuged (1300g, 10-min, 4 °C). Plasma was removed and stored in tubes at −80 °C until assayed. Concentration of total RO4929097 in plasma (i.e. free and protein bound drug) was determined by reversed-phase high performance liquid chromatography with mass spectrometric detection as previously described, with minor modiications [17] . The analytical method was validated according to current recommendations [18] . RO4929097 was determined with an interday accuracy of 101.2 % and a precision of 2.1 % at the 2.5-ng/mL lower limit of quantitation.
RO4929097 plasma concentration-time curves were analyzed by standard noncompartmental methods using WinNonlin Professional 5.0 software (Pharsight Corp., Cary, NC) [19] . The maximum concentration of drug in plasma (C max ) was the observed maximum value for the set of samples obtained for each dosing interval. Area under the plasma concentration-time curve from time zero to 24 h after dosing (AUC 24 ) was estimated by the logarithmic-linear trapezoidal algorithm. Pharmacokinetic parameters are reported as the geometric mean ± SD of values for individual patients at each dose level [20, 21] .
Statistical analyses
The primary objective of this study was to deine the MTD of R04929097 in combination with bevacizumab in patients with recurrent MGs using a standard 3 + 3 design. The study also intended to assess over all safety of the treatment and assess the pharmacokinetics of the combination of R04929097 with bevacizumab of the phase I part of the study. Data are presented with standard descriptive summaries. Observed toxicities are summarized based on CTCAE v4.0 with relationship of possible, probable, and deinitely to the combination regimen. Response rate is presented as percentage along with 95 % conidence interval (exact method). Survival probability was estimated 1 3 using the Kaplan-Meier method. The conidence interval of median time survival was constructed by the method of Brookmeyer-Crowley. All analyses were conducted using the SAS software (version 9.3, SAS Institute).
Results
Subject characteristics
A total of 13 recurrent MG patients were treated with RO4929097 in combination with bevacizumab. 1 treated patient was ineligible for the trial. The analysis data for toxicity included all 13 treated patients, while the analytical dataset for the trial results other than toxicity included the 12 eligible patients only.
The median age of the study patients was 56 years (range: 42-62). 7 patients were male (58 %) and 5 were female. 11 of the 12 patients (92 %) had a KPS ≥ 80. 8 patients had 1 prior relapse, while 1 patient had 3 prior relapses. 11 patients had at least a subtotal resection, and 10 patients had GBM.
Toxicities
There were three grade 3 toxicities (one with fatigue, two with hypertension) and three grade 4 toxicities (colonic perforation, thrombocytopenia, and sigmoidectomy) that were possibly, probably, or deinitely related to either RO4929097, bevacizumab, or both. The most common grade 2 toxicities were fatigue (23 %), headache (15 %), hypertension (15 %), and hypophosphatemia (15 %). The most common grade 1 toxicities included neutropenia (38 %), thrombocytopenia (31 %), elevated ALT (31 %), elevated AST (23 %), and fatigue (23 %) ( Table 1) .
Four patients were enrolled at the lowest (5 mg/kg) dose level of RO4929097. There was no grade 4 toxicity at this dose level. One patient had grade 3 fatigue and one had grade 3 hypertension. The remaining toxicities were grades 1 and 2. Initially three additional patients were enrolled in the next dose cohort (10 mg/kg). There was no grade 3 toxicity. One patient developed grade 4 colonic perforation and had a subsequent sigmoidectomy. This adverse event was a known side efect of bevacizumab and was felt to deinitely be related to bevacizumab alone, and not secondary to RO4929097. Three more patients were subsequently enrolled at this dose level without additional grade 3 or 4 toxicity. Thus, the trial proceeded to the 3rd and highest dose level (20 mg/kg). At this dose level, there was one grade 3 toxicity (hypertension) and one grade 2 toxicity (headache); the remaining toxicities at this cohort were grade 1. An additional three study patients were planned to enroll at this dose cohort in order to conirm this dose to be the MTD. However, Roche decided to halt patient enrollment in clinical trials involving RO4929097 and cease production of the drug as well as all further clinical development of RO4929097. Thus, the three conirmatory patients could not be enrolled at 20 mg/kg. The recommended phase II dose was 10 mg/kg of RO4929097 orally for 3 days on/4 days of each week in combination with bevacizumab. However, it is possible that had three additional trial patients been enrolled at the highest cohort, 20 mg/kg of RO4929097 may have been the recommended phase II dose.
Pharmacokinetics
The plasma pharmacokinetics of RO4929097 for a single 24 h dosing interval was characterized when given alone and together with bevacizumab in a total of 13 patients during treatment with daily oral doses of 5, 10, or 20 mg. Mean values of the C max and AUC 24 determined at each dose level are presented in Table 2 . The mean C max increased less than proportionately with escalation of the dose from 5 to 20 mg. The mean AUC 24 for patients receiving the 10 mg dose was approximately twofold greater than achieved with the 5 mg dose and essentially the same as the 20 mg dose. Diferences between the mean values of C max and AUC 24 when given alone and following the second biweekly dose of bevacizumab were less than 15 % at each dose level evaluated.
Response rates
Two (both GBM) of 12 patients (17 %, 95 % CI: 2-48 %) had radiographic responses according to the RANO criteria. One patient had a CR (Fig. 1) , and another patient had a PR.
Survival outcomes
At the last follow-up 10 of the 12 patients had died while 2 were still alive. Median OS was 10.9 months (95 % CI: 4-13.3 months). The median PFS was 3.7 months (95 % CI: 1.9-5.7 months). Figure 2 demonstrates the Kaplan-Meier plot for OS and PFS of the study cohort. 2 of 12 patients (17, 95 % CI: 2-48 %) were free of disease progression at 6 months from treatment initiation.
Tissue biomarker analysis: NICD staining of subject tissues
Pretreated tumor tissues were available for 9 of 13 enrolled subjects. Glioma tissues from all nine subjects demonstrated expression of NICD, indicative of cellular notch activation (Fig. 3) . Staining intensity was categorized into three groups: Strong, Moderate, and Weak.
Discussion
There is a critical need to identify more efective therapies for recurrent MG patients. The rationale for combining bevacizumab with a GSI, a notch signaling inhibitor, was based on the hypothesis that notch inhibition may ofset development of aggressive cellular behavior seen in bevacizumab refractory cases. Notch signaling has been reported to: (1) Stimulate migration of cancer cells [22, 23] ; (2) Play a key role in the activation of cellular hypoxic response by stabilizing HIF-1α [24, 25] ; (3) Directly regulate stemness of neural stem cells [26] . Considering that hypoxia in a HIF-1α dependent manner reprograms cells to a stem-like phenotype, inhibition of notch signaling may promote cellular diferentiation [27, 28] . Also, the addition of a notch signaling inhibitor to bevacizumab may allow for sustained inhibition of VEGF signaling with attenuation or delay in the development of iniltrative glioma response [29] . A recent study showing hypoxia can enhance γ-secretase activity through a HIF-1α mediated mechanism further validates our strategy of combined inhibition of notch and VEGF [30] . The aim of this study was to determine a potential MTD dose of the gamma-secretase inhibitor RO4929097 when given concurrently with bevacizumab. Although there was one DLT (grade 4 colonic perforation) at the second dose cohort (10 mg/kg), this was most likely a bevacizumabrelated efect, as this is a well described complication of bevacizumab. Additional study patients enrolled at this dose level did not have any grade 3 or 4 toxicity. There was one grade 3 toxicity and no grade 4 toxicity at the highest dose level (20 mg/kg). However, since the study sponsor decided to discontinue production of RO4929097, the inal recommended phase II dose of RO4929097 with bevacizumab was 10 mg/kg.
A secondary objective of this clinical trial was to determine if the plasma pharmacokinetics of RO4929097 was afected when given in combination with bevacizumab. Hepatic metabolism mediated by CYP3A4 appears to be a major route of elimination for RO4929097. RO4929097 induces CYP3A4 at doses as low as 10-20 mg in cancer patients and it has been shown to increase its own elimination upon repeated daily administration at doses greater than 24 mg [31, 32] . Bevacizumab is not a substrate or modulator of the hepatic CYP450 enzyme system and an efect on the hepatic metabolism of RO4929097 was not anticipated [33] .
Information on the plasma pharmacokinetics of total RO4929097 when given orally as a single agent was described in reports of two phase I clinical trials in patients with advanced solid tumors [31, 34] . The mean AUC 24 for the initial 10 mg dose of RO4929097 given to patients with MGs (2385 ± 606 ng·h/mL) in the present investigation was in very good agreement with the results when the Staining intensities were divided into high, moderate, and low expression. Nuclear counter staining (Dapi) is shown in blue 10 mg dose was combined with cediranib (38). However, unlike in these two previously reported studies, escalating the daily dose to 20 mg did not result in a signiicant increase in the mean AUC 24 (2232 ± 781 ng·h/mL). Factors that could account for the apparent decrease in the bioavailability of RO4929097 in patients at the 20 mg dose level were not evident. The pathophysiological characteristics of the patients and their use of concurrent supporting medications were comparable at each dose level in this study. Nevertheless, the results of these studies served to conclusively demonstrate that bevacizumab did not have a clinically signiicant efect on the pharmacokinetics of RO4929097.
The median OS and PFS results were reported. Deinitive conclusions regarding eicacy, however, cannot be made with such few study subjects. Furthermore, radiologic response observed in two subjects may merely relect bevacizumab efect. Recurrent MG patients do not have efective therapies and as such, treatment combinations that have even modest eicacy would be highly desirable in this patient population. The combination of RO4929097 and bevacizumab was well-tolerated. Although this particular gamma-secretase inhibitor is no longer being produced, given the compelling scientiic rationale and experience of targeting this pathway by other groups, additional studies combining antiangiogenic agents with Notch pathway inhibitors should be further explored [35] .
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